Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Matt Phipps

Argenx’s Next Blockbuster? Stock Jumps 12% After Phase 3 Myositis Trial Hits Key Goal

Argenx SE (NASDAQ:ARGX) stock jumped about 12% in Monday’s premarket trading after the company reported positive topline results from its Phase 3 ALKIVIA study.

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

As per a media report over the weekend, AstraZeneca Plc (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) are in potential discussions to form a pharmaceutical giant valued at nearly $400 billion.

Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After Irregularities

Bristol Myers Squibb Co. (NYSE:BMY) on Wednesday said it would enroll additional patients in the ADEPT-2 Phase 3 study.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Janux Therapeutics Stock Hits 52-Week Low After Trial Update

Janux Therapeutics Inc. (NASDAQ:JANX) stock hit a 52-week low on Tuesday after the company released updated interim data for its JANX007 Phase 1 program for metastatic castration-resistant prostate cancer (mCRPC).

Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy

Bristol Myers Squibb Co. (NYSE:BMY), in collaboration with Johnson Johnson (NYSE:JNJ), announced Friday that they decided to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added to the standard of care (conventional antiplatelet therapy) for patients after a recent acute coronary syndrome (ACS)…

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity

William Blair initiated coverage for Climb Bio (NASDAQ:CLYM), citing the potential of the company’s budoprutug, under development for autoimmune indications, including:

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug

On Wednesday, Amgen Inc. (NASDAQ:AMGN) and its partner Zai Lab (NASDAQ:ZLAB) said the final analysis of the Phase 3 FORTITUDE-101 trial evaluating bemarituzumab in combination with chemotherapy (mFOLFOX6) in first-line gastric cancer has been completed.

inkl

Read news from The Economist, FT, and more,
with one subscription

Lung Disease-Focused Insmed 'Must-Own' Name For Investors

Lung Disease-Focused Insmed 'Must-Own' Name For Investors

William Blair initiated coverage on Insmed Incorporated (NASDAQ:INSM), citing that the clinical and commercial execution of its drugs can significantly increase Insmed's valuation.

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

AstraZeneca Plc

Bristol Myers Squibb

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Prostate Cancer

Places

416,724 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play